Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | HTR6 | P50406 | 8/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1964662 | 0.88 | CYP2C19 (0.57) | CYP2C19HTR6MEN1KMT2AALDH1A1 | |
| SCHEMBL15091424 | 0.87 | L3MBTL1 (0.59) | CYP2C19HTR6ALDH1A1TSHRHTT | |
| SCHEMBL17165144 | 0.84 | CYP2C19 (0.52) | CYP2C19HTR6MEN1KMT2AALDH1A1 | |
| SCHEMBL17165143 | 0.84 | CYP2C19 (0.52) | CYP2C19HTR6MEN1KMT2AALDH1A1 | |
| SCHEMBL10142546 | 0.81 | CYP2C19 (0.61) | CYP2C19HTR6MEN1KMT2AALDH1A1 | |
| SCHEMBL1960656 | 0.81 | CYP2C19 (0.61) | CYP2C19HTR6MEN1KMT2AALDH1A1 | |
| SCHEMBL299699 | 0.81 | CYP2C19 (0.61) | CYP2C19HTR6MEN1KMT2AALDH1A1 | |
| SCHEMBL1958833 | 0.81 | CYP2C19 (0.61) | CYP2C19HTR6MEN1KMT2AALDH1A1 | |
| SCHEMBL18346376 | 0.81 | CYP2C19 (0.61) | CYP2C19HTR6MEN1KMT2AALDH1A1 | |
| SCHEMBL1962403 | 0.81 | CYP2C19 (0.61) | CYP2C19HTR6MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233797-B1 | MAP4K4 (HGK) INHIBITORS | Sri int inc (US) | 2019-05-08 | — | — | EP | disclosed |
| US-10000451-B2 | MAP4K4 (HGK) inhibitors | SRI INTERNATIONAL (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170320824-A1 | MAP4K4 (HGK) Inhibitors | SRI INTERNATIONAL (US) | 2017-11-09 | — | — | US | disclosed |
| EP-3233797-A1 | MAP4K4 (HGK) Inhibitors | SRI International Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016114816-A1 | MAP4K4 (HGK) Inhibitors | SRI INTERNATIONAL (US) | 2016-07-21 | — | — | WO | disclosed |
| EP-2660238-B1 | Compounds for the prevention and treatment of cardiovascular disease | RESVERLOGIX CORP (CA) | 2015-05-06 | — | — | EP | disclosed |
| US-8952021-B2 | Compounds for the prevention and treatment of cardiovascular disease | RESVERLOGIX CORP. (CA) | 2015-02-10 | — | — | US | disclosed |
| EP-2382194-B1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE | RESVERLOGIX CORP (CA) | 2014-03-12 | — | — | EP | disclosed |
| EP-2660238-A1 | Compounds for the prevention and treatment of cardiovascular disease | RESVERLOGIX CORP. (CA) | 2013-11-06 | — | — | EP | disclosed |
| US-20110294807-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE | RESVERLOGIX CORP. (CA) | 2011-12-01 | — | — | US | disclosed |
| EP-2382194-A2 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE | RESVERLOGIX CORP. (CA) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010079431-A2 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE | RESVERLOGIX CORP. (CA) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320824-A1 | MAP4K4 (HGK) Inhibitors | MAP4K4, MAP4K2, MAP4K3 | CYP2C19 2086/4885HTR6 4239/4885MEN1 998/4885 |
| US-20110294807-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE | APOB, APOL1, LDLR | CYP2C19 2445/4885HTR6 1562/4885MEN1 4554/4885 |
| US-10000451-B2 | MAP4K4 (HGK) inhibitors | MAP4K4, MAP4K2, MAP4K3 | CYP2C19 2086/4885HTR6 4239/4885MEN1 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.